Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07415590

Ketogenic Diet for Post-Traumatic Stress Disorder (PTSD)

This project is a prospective, single-arm, open-label feasibility study testing whether a 12-week medically supervised ketogenic diet (KD) can be implemented in adults with PTSD in Germany (N=6). The primary aim is feasibility: recruitment (N=6 within a predefined timeframe), adherence to ketosis measured by daily capillary β-hydroxybutyrate (BHB), completion of study assessments (including daily EMA symptom/BHB reporting), and retention through the post-intervention visit. Secondary outcomes include participant self-reported feasibility at week 12. Exploratory outcomes include descriptive changes in PTSD symptoms/mental health and metabolic/inflammatory/mitochondrial biomarkers as well as associations between biomarkers and PTSD symptoms. The study is not powered for efficacy; results will inform the design of a larger clinical trial.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hochschulambulanz der Universität der Bundeswehr München, München, Bavaria, Germany

Loading trial locations.

About this study

Post-traumatic stress disorder (PTSD) is characterized by intrusive re-experiencing of traumatic events and clinically relevant impairments in mood and functioning. In Germany, PTSD affects a meaningful proportion of the general population and is particularly prevalent in refugee populations. Although trauma-focused psychotherapies are considered first-line treatments, many patients face access barriers and high dropout rates, and currently available pharmacological approaches show limited remission rates.

Emerging evidence suggests that PTSD is associated with trauma-related metabolic dysregulation, including inflammatory processes and mitochondrial impairments. Ketogenic therapy - most commonly implemented via a ketogenic diet (KD) - is a metabolic intervention with documented neuroprotective and anti-inflammatory properties and early evidence of benefit across several psychiatric conditions. Given the overlap between proposed KD mechanisms and PTSD pathophysiology, evaluating KD as a potential intervention for PTSD is a promising and novel research direction. However, prospective feasibility data in German PTSD cohorts are currently lacking, which justifies a human pilot trial under real-world clinical conditions.

This study is a 12-week, single-arm, open-label feasibility trial in six adults with verified PTSD living in Germany. The primary objective is to evaluate feasibility with respect to recruitment, adherence to ketosis, completion of study assessments, and retention. Secondary objectives assess participant-reported feasibility. Exploratory objectives include changes in PTSD symptoms and general mental health, associations between daily capillary β-hydroxybutyrate (BHB) levels and daily symptom severity, identification of barriers and facilitators relevant to future trials, and descriptive changes in metabolic, inflammatory, and mitochondrial markers. Participants will receive a medically supervised, individually tailored KD with structured dietary support. Adherence and symptom trajectories will be monitored via daily BHB measurements and brief daily self-reports.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mental capacity to provide informed consent
  • Provides written confirmation of informed consent
  • Adults (18-65 years)
  • Verified PTSD diagnosis according to DSM 5-TR or ICD-11
  • Currently living in Germany
  • High treatment motivation (score > 7/10)
  • Consent to information sharing within study staff (release from medical confidentiality)
  • No medical or psychiatric contraindication

Exclusion criteria

  • Pregnant or breastfeeding
  • Active alcohol or drug misuse
  • BMI < 18.5
  • Currently medicated with glucocorticoids, lithium, anticonvulsants, hypertension medication, glucose-lowering medications, or SGLT-2 inhibitor medications
  • Diagnosed with type 1 or type 2 diabetes
  • Diagnosed with severely impaired kidney function
  • Diagnosed with ESLD (End Stage Liver Disease) or ESRD (End Stage Renal Disease)
  • Follows a vegan diet
  • History of eating disorders
  • Acute or chronic suicidality
  • Acute or chronic self-injury behavior
  • Acute positive psychotic/manic symptomatology
  • Already following a ketogenic diet within the past 6 weeks
  • Any change to psychiatric medication regimen in past 6 weeks
  • Severe hypercholesterolemia (may represent genetic metabolic disorder)
  • Porphyria, heart failure, pancreatitis
  • Institutionally dependent individuals

Treatment and study plan

Ketogenic diet

Other

Participants will undergo a medically supervised ketogenic dietary intervention, individually tailored to achieve and maintain low-level ketosis (β-hydroxybutyrate [BHB] concentrations typically ≥ 0.5 mmol/L) within two weeks.

Depending on individual response and tolerability, participants may gradually adjust their dietary composition (e.g., by increasing the proportion of fat relative to protein and carbohydrates) to reach higher levels of ketosis (BHB typically ≥ 2.0 mmol/L) as an optional target. The dietary intervention will be guided and monitored by qualified dietitians under medical supervision.

Primary outcomes

  1. Process Feasibility

    Time frame: Intervention: 12 weeks

    The primary endpoints assess feasibility based on recruitment success, adherence to the ketogenic intervention, completion of study assessments, and participant retention over the 12-week intervention period.

Secondary outcomes

  1. Self-report feasibility

    Time frame: Intervention: 12 weeks

    Participant self-reported feasibility will be assessed at the end of the intervention using brief quantitative ratings and open-ended questions, with qualitative feedback used to contextualize the quantitative results.

Other outcomes

  1. Symptom Changes and Metabolic Markers

    Time frame: Intervention: 12 weeks

    Exploratory outcomes include psychological outcomes such as changes in PTSD symptom severity, mental health, and functioning, as well as daily PTSD symptom monitoring and beta-hydroxybuterate measurements to examine temporal relationships between ketone levels and symptom fluctuations. In addition, physiological and metabolic parameters - including inflammatory and mitochondrial markers as well as immunometabolic analyses - will be collected to explore pathophysiological mechanisms.

Sponsors and collaborators

Lead sponsor

Bundeswehr University Munich

Other

Collaborators

  • LMU Klinikum

Registry information

Official study title

Ketogenic Diet in the Treatment of PTSD in Germany: A Single-Arm Feasibility Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 17, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.